Neurocrine plans $77M secondary as it advances PhII endometriosis drug elagolix
This article was originally published in Scrip
Executive Summary
Neurocrine Biosciences said it intends to raise $77 million by selling 9.5 million shares $8.10 per share, in an underwritten public offering scheduled to close near the end of January. The price is a 6.3% discount to its closing price of $8.64 on 18 January.